ATAD1 and infection: Based on findings acquisition of antibodies against the MSP1 Block 2 could associate with clinical immunity and reduced risk of infection with Plasmodium vivax; a comprehensive understanding of genetic variation of the promise malaria vaccine candidate would be important for the rationale of malaria vaccine designs.